Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Cutaneous Melanoma — Systemic Therapy

First-line Second-line SECOND-LINE Cutaneous melanoma Resected, high-risk (IIB–III) Metastatic · 1L immunotherapy BRAF V600-mutant Later-line Adjuvant IO Adjuvant pembrolizumab or nivolumab CheckMate 238 / KEYNOTE-054 ↗ BRAF+ Dabrafenib + trametinib COMBI-AD ↗ Neoadjuvant Neoadjuvant pembrolizumab S1801 ↗ Dual-IO Nivolumab + ipilimumab CheckMate 067 ↗ LAG-3 Nivolumab + relatlimab RELATIVITY-047 ↗ Mono Anti-PD-1 monotherapy KEYNOTE-006 ↗ Targeted Dabrafenib + trametinib COMBI-d ↗ Targeted Encorafenib + binimetinib COLUMBUS ↗ TIL Lifileucel (TIL therapy) post-anti-PD-1 ↗ If not used BRAF/MEK or clinical trial sequence-dependent ↗